Back to results
US 2023/0151118 A1Published application
Artc1 ligands for cancer treatment
AssigneesUniversitäT ZüRich, Universitätsklinikum Hamburg-Eppendorf
InventorsFriedrich NOLTE, Stephan MENZEL, Tobias SUTER, Michael HOTTIGER, Denise DORVIGNIT-PEDROSO, Jesus GLAUS-GARZON, Kathrin NOWAK, Fabio AIMI
Life of this patent
Estimating the term…
Abstract
The present invention relates to a non-agonist ligand of ARTC1, which inhibits the ADP-ribosyltransferase activity of ARTC1, or an inhibitor nucleic acid sequence capable of downregulating or inhibiting expression of a target nucleic acid sequence encoding ARTC1, for use in prevention or treatment of cancer. The invention also relates to a method for diagnosis of cancer.
Claims19
A method for treating a cancer, comprising:
- administering to a subject in need thereof a non-agonist ligand of ARTC1, thereby treating the cancer.
A method for treating a cancer, comprising
- administering to a subject in need thereof an inhibitor nucleic acid sequence capable of downregulating or inhibiting expression of a target nucleic acid sequence encoding ARTC1,
- thereby treating the cancer.
Dependencies are inferred from the claim text.